Daratumumab Recruiting Phase 1 Trials for Multiple Myeloma (MM) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02519452A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
NCT02955810Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)